株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品分析:フォシーガ (Farxiga)

Farxiga

発行 Datamonitor Healthcare 商品コード 603953
出版日 ページ情報 英文 54 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
医薬品分析:フォシーガ (Farxiga) Farxiga
出版日: 2019年02月07日 ページ情報: 英文 54 Pages
概要

フォシーガ (ダパグリフロジン) は、ナトリウム・グルコース共輸送体2 (SGLT2) に対する阻害剤で、2型糖尿病の治療薬として承認されており、1型糖尿病の治療薬として第III相試験中です。

当レポートでは、フォシーガ (ダパグリフロジン) について調査分析し、製品プロファイルについて、体系的な情報を提供しています。

製品プロファイル

  • フォシーガ (Farxiga) :2型糖尿病
  • フォシーガ (Farxiga) :1型糖尿病
目次
Product Code: DMKC0080869

Overview

Farxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Farxiga: Diabetic nephropathy
    • Farxiga: Diabetes type 1
    • Farxiga: Chronic heart failure (CHF)
    • Farxiga: Diabetes type 2

LIST OF FIGURES

  • Figure 1: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 3: Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Farxiga for type 1 diabetes - SWOT analysis
  • Figure 5: Datamonitor Healthcare's drug assessment of Farxiga in type 1 diabetes
  • Figure 6: Datamonitor Healthcare's drug assessment of Farxiga in type 1 diabetes
  • Figure 7: Farxiga for chronic heart failure - SWOT analysis
  • Figure 8: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Farxiga for chronic heart failure
  • Figure 10: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 11: Farxiga for type 2 diabetes - SWOT analysis
  • Figure 12: Datamonitor Healthcare drug assessment of Farxiga
  • Figure 13: Datamonitor Healthcare drug assessment scorecard for Farxiga compared to Januvia
  • Figure 14: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 15: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Farxiga drug profile
  • Table 2: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
  • Table 3: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
  • Table 4: Farxiga for diabetic nephropathy - SWOT analysis
  • Table 5: Farxiga drug profile
  • Table 6: Farxiga late-phase trials in type 1 diabetes
  • Table 7: Farxiga drug profile
  • Table 8: Farxiga Phase III trials in chronic heart failure
  • Table 9: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 10: Farxiga franchise products
  • Table 11: Farxiga drug profile
  • Table 12: Xigduo drug profile
  • Table 13: Overview of pivotal trial data for Farxiga in diabetes
  • Table 14: Key planned and ongoing Phase III clinical trials for Farxiga in diabetes
  • Table 15: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 16: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25